1,1,1-trifluoro-4-(2-methanesulfonylphenyl)-4-methylpentan-2-one | 1198785-21-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1,1,1-trifluoro-4-(2-methanesulfonylphenyl)-4-methylpentan-2-one
• 英文别名: 1,1,1-trifluoro-4-methyl-4-(2-methylsulfonylphenyl)pentan-2-one
• CAS: 1198785-21-5
• 化学式: C₁₃H₁₅F₃O₃S
• 分子量: 308.322
• InChiKey: OOGPBJCMDVRXSE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  59.6
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1,1,1-trifluoro-4-(2-methanesulfonylphenyl)-4-methylpentan-2-one 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 potassium tert-butylate 、 三乙胺 、 氢化铝 、 mercury dichloride 作用下， 以 四氢呋喃 、 N-甲基吡咯烷酮 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 35.0h， 生成 1,1,1-trifluoro-4-(2-methanesulfonylphenyl)-4-methyl-2-(5H-pyrrolo[3,2-d]pyrimidin-6-ylmethyl)pentan-2-ol
  参考文献：
  名称：

  Identification of Highly Efficacious Glucocorticoid Receptor Agonists with a Potential for Reduced Clinical Bone Side Effects

  摘要：

  Synthesis and structure-activity relationship (SAR) of a series of nonsteroidal glucocorticoid receptor (GR) agonists are described. These compounds contain "diazaindole" moieties and display different transcriptional regulatory profiles in vitro and are considered "dissociated" between gene transrepression and transactivation. The lead optimization effort described in this article focused in particular on limiting the transactivation of genes which result in bone side effects and these were assessed in vitro in MG-63 osteosarcoma cells, leading to the identification of (R)-18 and (R)-21. These compounds maintained anti-inflammatory activity in vivo in collagen induced arthritis studies in mouse but had reduced effects on bone relevant parameters compared to the widely used synthetic glucocorticoid prednisolone 2 in vivo. To our knowledge, we are the first to report on selective glucocorticoid ligands with reduced bone loss in a preclinical in vivo model.

  DOI：

  10.1021/jm4019178
• 作为产物：
  描述：

  2-溴茴香硫醚 在 ruthenium trichloride 、 sodium periodate 、 magnesium 作用下， 以 四氢呋喃 、 水 、 乙腈 为溶剂， 反应 20.5h， 生成 1,1,1-trifluoro-4-(2-methanesulfonylphenyl)-4-methylpentan-2-one
  参考文献：
  名称：

  Optimization of Drug-Like Properties of Nonsteroidal Glucocorticoid Mimetics and Identification of a Clinical Candidate

  摘要：

  A series of nonsteroidal dissociated glucocorticoid receptor agonists was optimized for drug-like properties such as cytochrome P450 inhibition, metabolic stability, aqueous solubility, and hERG ion channel inhibition. This effort culminated in the identification of the clinical candidate compound (R)-39.

  DOI：

  10.1021/ml500387y

文献信息

• Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof
  申请人：Harcken Christian

  公开号：US20090325988A1

  公开（公告）日：2009-12-31

  Compounds of Formula (I) wherein R 1 , R 2 , X, and Y are as defined herein, or a tautomer, optical isomer, prodrug, co-crystal, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

  化合物的公式（I），其中R1，R2，X和Y的定义如本文所述，或其互变异构体，光学异构体，前药，共晶体或盐；含有这些化合物的药物组合物，以及使用这些化合物调节糖皮质激素受体功能的方法，治疗由糖皮质激素受体功能介导或以炎症，过敏或增殖过程为特征的疾病状态或病情的方法。
• Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
  申请人：Boehringer Ingelheim International GmbH

  公开号：US08268859B2

  公开（公告）日：2012-09-18

  Compounds of Formula (I) wherein R1, R2, X, and Y are as defined herein, or a tautomer, optical isomer, prodrug, co-crystal, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

  公式（I）的化合物，其中R1，R2，X和Y的定义如本文所述，或其互变异构体，光学异构体，前药，共晶体或盐；包含这些化合物的制药组合物以及使用这些化合物调节糖皮质激素受体功能的方法，以及治疗由糖皮质激素受体功能介导或以炎症，过敏或增殖过程为特征的疾病状态或病情的方法。
• Optimization of Drug-Like Properties of Nonsteroidal Glucocorticoid Mimetics and Identification of a Clinical Candidate
  作者：Christian Harcken、Doris Riether、Pingrong Liu、Hossein Razavi、Usha Patel、Thomas Lee、Todd Bosanac、Yancey Ward、Mark Ralph、Zhidong Chen、Donald Souza、Richard M. Nelson、Alison Kukulka、Tazmeen N. Fadra-Khan、Ljiljana Zuvela-Jelaska、Mita Patel、David S. Thomson、Gerald H. Nabozny

  DOI：10.1021/ml500387y

  日期：2014.12.11

  A series of nonsteroidal dissociated glucocorticoid receptor agonists was optimized for drug-like properties such as cytochrome P450 inhibition, metabolic stability, aqueous solubility, and hERG ion channel inhibition. This effort culminated in the identification of the clinical candidate compound (R)-39.
• [EN] GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF<br/>[FR] MIMÉTIQUES DE GLUCOCORTICOÏDES, LEURS PROCÉDÉS DE FABRICATION, DES COMPOSITIONS PHARMACEUTIQUES ET LEURS UTILISATIONS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009149139A8

  公开（公告）日：2011-02-24
• GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2300472A1

  公开（公告）日：2011-03-30